TARGIT IORT for breast cancer with low to moderate risk of recurrence

Eligible for TARGIT-B trial, but could also have TARGIT IORT as the definitive radiotherapy

Discuss in multidisciplinary team

Offer TARGIT-B (boost) either within the TARGIT-B trial or as definitive tumour bed boost


Offer Intrabeam TARGIT IORT as the definitive radiotherapy*


*In 15-20% of cases, in if high risk factors are seen postoperatively, then whole breast radiotherapy (without a tumour bed boost) should be recommended